Merck KGaA Denied Rights To ImClone Antibody As Part Of Erbitux Partnership
This article was originally published in The Pink Sheet Daily
Executive Summary
ImClone’s agreement with Bristol for Erbitux in North America does cover the follow-on antibody IMC-11F8.